PKDCC: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Autoimmune Disabilities

Target Name: PKDCC

NCBI ID: G91461

PKDCC: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Autoimmune Disabilities

PKDCC (Protein Kinase DCC) is a gene that encodes a protein known as PKDCC. PKDCC is a non-catalytic protein that plays a crucial role in the regulation of cellular processes. It is a protein that is expressed in various tissues and organs, including the brain, heart, and kidneys.

PKDCC functions as a negative regulator of the protein kinase CAK (Ca2+-ATPase), which is a key enzyme involved in cell signaling. When CAK is activated, it causes cells to multiply and differentiate. However, when PKDCC is activated, it inhibits the activity of CAK, which leads to the suppression of cell proliferation and differentiation.

PKDCC has been shown to play a role in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. It has also been identified as a potential drug target. Researchers are investigating the potential therapeutic benefits of targeting PKDCC in these diseases.

One of the potential benefits of targeting PKDCC is its potential to treat cancer. Cancer is a leading cause of death worldwide, and there is a high demand for new and effective treatments. PKDCC has been shown to play a role in the development and progression of various types of cancer.

For example, studies have shown that PKDCC is highly expressed in various types of cancer, including breast, lung, and ovarian cancer. Additionally, studies have shown that inhibiting PKDCC activity can lead to the regression of cancer cells. This suggests that targeting PKDCC may be an effective way to treat cancer.

Another potential benefit of targeting PKDCC is its potential to treat neurodegenerative diseases. Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are progressive and terminal diseases that cause the gradual loss of brain cells. There is currently no cure for these diseases, and there is a high demand for new and effective treatments.

PKDCC has been shown to play a role in the development and progression of neurodegenerative diseases. Studies have shown that PKDCC is highly expressed in the brains of individuals with neurodegenerative diseases, and that its activity is closely correlated with the severity of these diseases.

Additionally, studies have shown that inhibiting PKDCC activity can lead to the regression of neurodegenerative diseases. This suggests that targeting PKDCC may be an effective way to treat neurodegenerative diseases.

PKDCC has also been shown to play a role in the development and progression of autoimmune diseases. Autoimmune diseases, such as rheumatoid arthritis, lupus, and multiple sclerosis, are diseases in which the immune system attacks the body's own tissues. There is currently no cure for these diseases, and there is a high demand for new and effective treatments.

PKDCC has been shown to play a role in the development and progression of autoimmune diseases. Studies have shown that PKDCC is highly expressed in the tissues of individuals with autoimmune diseases, and that its activity is closely correlated with the severity of these diseases.

In conclusion, PKDCC is a gene that encodes a protein that plays a crucial role in the regulation of cellular processes. It has been shown to play a role in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. As a result, PKDCC is an attractive drug target for researchers to investigate the potential therapeutic benefits of targeting it in these diseases.

Protein Name: Protein Kinase Domain Containing, Cytoplasmic

Functions: Secreted tyrosine-protein kinase that mediates phosphorylation of extracellular proteins and endogenous proteins in the secretory pathway, which is essential for patterning at organogenesis stages. Mediates phosphorylation of MMP1, MMP13, MMP14, MMP19 and ERP29 (PubMed:25171405). Probably plays a role in platelets: rapidly and quantitatively secreted from platelets in response to stimulation of platelet degranulation (PubMed:25171405). May also have serine/threonine protein kinase activity. Required for longitudinal bone growth through regulation of chondrocyte differentiation. May be indirectly involved in protein transport from the Golgi apparatus to the plasma membrane (By similarity)

More Common Targets